

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of
ULRICH et al.

Group Art Unit: 1631

Serial No.: not known

Examiner: Allen, M.

Divisional app. of 08/882,431

Filed: January 29, 2004

FOR: BACTERIAL SUPERANTIGEN VACCINES

* * * * *

January 29, 2004

STATEMENT PURSUANT TO 37 CFR 1.98(d)

Hon. Commissioner of Patents
and Trademarks
Alexandria, VA 222313-1450

Sir:

In connection with the above-identified continuation application, Applicants have filed concurrently herewith an Information Disclosure Statement and corresponding PTO-1449 form citing a number of references. Copies of all the references cited on the PTO-1449 form were submitted and considered in parent application Serial No. 08/882,431 (filed 1-14-06, 2-22-99 and 4-16-03). Pursuant to 37 CFR 1.98(d), copies of these references are not required to be supplied in this continuation application.

By: 

Marlana K. Titus, Reg. No. 35,843
for: Elizabeth Arwine, Reg. No. 45,867
Attorney for Applicants
U.S. Army Medical Research
and Materiel Command
504 Scott St., ATTN: MCMR-JA
Fort Detrick, MD 21702-5012
(301) 977-7227

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
Army140D

In Re Application Of: **Ulrich et al.**

Serial No.
not known

Filing Date
January 29, 2004

Examiner
not known

Group Art Unit
not known

Title: **BACTERIAL SUPERANTIGEN VACCINES**

Address to:

**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
Army140D

In Re Application: Ulrich et al.

Serial No.
not known

Filing Date

Examiner
not known

Group Art Unit
not known

BACTERIAL SUPERANTIGEN VACCINES

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☐ The Director is hereby authorized to charge and credit Deposit Account No. _____ as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.


Signature

Dated: January 29, 2004

Marlana Titus, Reg No 35,843
for Elizabeth Arwine, Reg No 45,867
Attorney for applicant
U.S. Army Medical Research and Materiel Command
504 Scott Street
Fort Detrick, MD 21702-5012
(301) 977-7227

CC:

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

Army1402

Application Number

Div. 57 08/882,431

Applicant(s)

Ulrich et al.

Filing Date

1-29-04

Group Art Unit

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

A

Bavari et al., "Engineered Bacterial Superantigen Vaccines", Vaccines 96, pages 135-141 (1996).

B

Bavari et al., "Superantigen Vaccines: A Comparative Study of Genetically Attenuated Receptor-Binding Mutants of Staphylococcal Enterotoxin A", J. Infectious Diseases, 1996, 174:338-345.

C

Hurley et al., "Identification of Class II Major Histocompatibility Complex and T Cell Receptor Binding Sites in the Superantigen Toxic Shock Syndrome Toxin 1", J. Exp. Med., Vol. 181, 2229-2235, June 1995.

D

Stiles, et al., "Toxicity of Staphylococcal Enterotoxins Potentiated by Lipopolysaccharide: Major Histocompatibility Complex Class II Molecule Dependency and Cytokine Release", Infection and Immunity, Vol. 61, No. 12, pages 5333-5338, Dec. 1993.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and considered. Include copy of this form with next communication to applicant.

DATE: 1-29-04

Sheet 2 of 3

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

GROUP ART UNIT:

CLIENT /MATTER: Amy 140D

APPLICANT (inventors)
Ulrich ET AL.

EXAMINER

APPLICATION NO.
08/882,431

FILING DATE

1-29-04

U. S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Date Mo./Yr.	Name (Family Name of First Inventor)	Class	Subclass	Filing Date If appropriate
AR						
BR						
CR						
DR						
ER						
FR						
GR						
HR						
IR						
JR						
KR						

FOREIGN PATENT DOCUMENTS

	Document Number	Date Mo./Yr.	Country	English Abstract		Class	Subclass	Translation Available	
				Enclosed	No			Enclosed	No
NR									

OTHER DOCUMENTS (Including in this order, Author, Title, Periodical Name, Date, Pertinent Pages, Etc.)

QR	Dannecker et al. (1994) Activation of human T cells by the superantigen Staphylococcus enterotoxin B: Analysis on a cellular level. <i>Immunobiology</i> 190: 116-126.
RR	Gonzalo et al. (1992) Expansion and clonal deletion of peripheral T cells induced by bacterial superantigen is independent of the interleukin-2 pathway. <i>Eur. J. Immunol.</i> 22:1007-1011.
SR	Bavari et al. (1995) Genetically attenuated bacterial superantigen vaccines. <i>J. Cellular Biochemistry Suppl.</i> 21A, abstract C2-204 page 88.
TR	Bavari et al. (1995) Staphylococcal Enterotoxin A and toxin shock syndrome toxin compete with CD4 for human major histocompatibility complex class II binding. <i>Infection and Immunity</i> 63:423-429.
UR	Mahana et al. (1995) A natural mutation of the amino acid residue at position 60 destroys staphylococcal enterotoxin A murine T-cell mitogenicity. <i>Infection and Immunity</i> 63:2826-2832.
VR	Woody et al. (1998) Differential immune responses to Staphylococcal enterotoxin B mutations in a hydrophobic loop dominating the interface with major histocompatibility complex class II receptors. <i>J. Infectious Diseases</i> 177: 1013-1022.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE:

1-29-04

at 3 of 3

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

GROUP ART UNIT: UNKNOWN

CLIENT / MATTER: P

Army 140D

APPLICANT (inventors)
Ulrich ET AL.EXAMINER
UNKNOWNAPPLICATION NO.
UNKNOWN

FILING DATE

1-29-04

Div. of 08/882,431
U. S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Date Mo./Yr.	Name (Family Name of First Inventor)	Class	Subclass	Filing Date If appropriate
AR						
BR						
CR						
DR						
ER						
FR						
GR						
HR						
IR						
JR						
KR						

FOREIGN PATENT DOCUMENTS

	Document Number	Date Mo./Yr.	Country	English Abstract		Class	Subclass	Translation Available	
				Enclosed	No			Enclosed	No
NR									

OTHER DOCUMENTS (Including in this order, Author, Title, Periodical Name, Date, Pertinent Pages, Etc.)

QR	Bavari, S. et al. (1996) Superantigen vaccines: A comparative study of genetically attenuated receptor-binding mutants of Staphylococcal enterotoxin A. <i>J. Inf. Dis.</i> 174:338-345.
RR	Ulrich, R. G. et al. (1995) Staphylococcal enterotoxins A and B share a common structural motif for binding class II major histocompatibility complex molecules. <i>Nature Structural Biology</i> 2:554-560.
SR	Stiles, B. G. et al. (1993) Toxicity of Staphylococcal enterotoxins potentiated by lipopolysaccharide: major histocompatibility complex class II molecule dependency and cytokine release. <i>Infect. Immun.</i> 61:5333-5338.
TR	Hurley, J. M. et al. (1995) Identification of class II major histocompatibility complex and T cell receptor binding sites in the superantigen toxin shock syndrome toxin 1. <i>J. Exp. Med.</i> 181:2229-2234.
UR	Ulrich, R. G. et al. (1995) Bacterial superantigens in human disease: structure, function and diversity. <i>Trends in Microbiology</i> 3: 463-468.
VR	Bavari, S. et al. (1996) Engineered bacterial superantigen vaccines. In <i>Vaccines 96</i> , Cold Spring Harbor Laboratory Press, p. 135-141.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.